This inventor holds 4 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignee: Symphogen A/s. Active years: 2011-2013.
Location History:
- Copenhangen N, DK (2011)
- Copenhagen, DK (2012 - 2013)
- Lyngby, DK (2013)
Company Filing History:
Years Active: 2011-2013
Title: Per-Johan Meijer: Innovator in Cancer Therapy
Introduction
Per-Johan Meijer is a notable inventor based in Lyngby, Denmark. He has made significant contributions to the field of cancer therapy through his innovative work on therapeutic antibodies. With a total of 4 patents, Meijer's inventions focus on novel approaches to combat cancer.
Latest Patents
One of his latest patents is related to Anti-HER2 antibodies and compositions. This invention pertains to therapeutic antibodies directed against HER2 (ErbB2) and includes recombinant polyclonal anti-HER2 antibody compositions. These compositions are designed for the treatment of cancer. Another significant patent involves recombinant anti-epidermal growth factor receptor antibody compositions. This invention provides mixtures of antibodies capable of binding human EGFR, demonstrating synergy in reducing the proliferation of cancer cell lines. The innovative compositions have shown promising results in animal models, indicating a new mechanism of action for tumor eradication.
Career Highlights
Per-Johan Meijer is currently associated with Symphogen A/S, where he continues to advance his research in antibody therapies. His work has been pivotal in developing new treatments that leverage the body's immune response to fight cancer effectively.
Collaborations
Meijer has collaborated with notable colleagues such as Mikkel Wandahl Pedersen and Allan Jensen, contributing to the advancement of therapeutic antibody research.
Conclusion
Per-Johan Meijer stands out as an influential inventor in the realm of cancer therapy, with a focus on innovative antibody compositions. His contributions are paving the way for new treatment options in oncology.